The DNA and gene chip market size has grown rapidly in recent years. It will grow from $8.19 billion in 2024 to $9.27 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to genomic research advancements, rise of personalized medicine, human genome project milestones, drug discovery and development, disease biomarker identification.
The DNA and gene chip market size is expected to see rapid growth in the next few years. It will grow to $15.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in precision medicine, expansion of biomarker discovery, growth of personalized therapeutics, application in cancer research, increasing research funding. Major trends in the forecast period include technological advancements, product innovations, regulatory framework and compliance, focus on rare diseases, continuous reduction in costs.
The DNA and gene chip market is experiencing substantial growth, primarily fueled by the escalating demand for early cancer detection. Cancer, a pervasive health concern, prompts an urgent need for technologies facilitating timely identification. DNA and gene chips play a pivotal role in measuring gene expression, understanding genetic landscapes, and assessing genomic regulatory elements in cancer cells. Notably, the American Cancer Society estimates approximately 1.9 million new cancer cases and 609,360 deaths in the United States for 2022, emphasizing the critical role of DNA and gene chips in advancing early cancer detection.
The growing emphasis on personalized medicine is anticipated to drive the expansion of the DNA and gene chip market in the future. Personalized medicine is an emerging approach in healthcare that utilizes an individual's genetic profile to inform decisions regarding disease prevention, diagnosis, and treatment. DNA and gene chips play a crucial role in personalized medicine by analyzing a person's genetic profile to identify potential disease risks and treatment options. For example, in October 2022, reports from STAT, a US-based health-focused news organization, indicated that there were over 75,000 genetic testing products and 300 personalized medicines available. Consequently, the heightened focus on personalized medicine is fueling the growth of the DNA and gene chip market.
Strategic partnerships and collaborations are emerging as significant trends in the DNA and gene chip market. Many companies in this field are seeking alliances to enhance their positions within the DNA and gene chip market. For example, in June 2022, Avesthagen Limited, an India-based integrated systems biology platform company, established a four-year strategic partnership with Wipro Limited, an India-based information technology firm. This collaboration involves executing the project titled "Cancer Risk Assessed by NGS profiling of circulating free DNA and RNA for lung cancer," which focuses on genomics sequencing services. Additionally, in May 2022, Thermo Fisher Scientific, a US-based supplier of analytical instruments, partnered with the Qatar Genome Program (QGP), part of the Qatar Foundation (QF), to develop a custom Axiom genotyping array for pan-Arab populations using whole genome sequencing data from 19 Arab countries. This array, featuring 800,000 variants, aims to enhance genomic research on conditions such as diabetes, cardiovascular diseases, autism, and cancer. The collaboration supports Qatar's national vision for improved population health and the advancement of precision medicine for Arab individuals globally, facilitated by Thermo Fisher's Axiom microarray technology, which accelerates precision medicine initiatives.
Key players in the DNA and gene chip market are developing innovative genotyping chips, such as the Axiom YNS_Mol1, to advance the food industry and promote insect consumption. The Axiom YNS_Mol1 is a genotyping chip specifically designed for insect breeding, particularly for the Tenebrio Molitor mealworm. For instance, in June 2023, Ÿnsect, a France-based company specializing in insect production, introduced the world's first genotyping chip for insect breeding, the Axiom YNS_Mol1. Developed in collaboration with Thermo Fisher Scientific, this pioneering chip aims to transform insect breeding for sustainable food and pet food production. It analyzes genetic traits to enhance genomic diversity and improve characteristics such as growth, reproduction, and disease resistance in Tenebrio Molitor mealworms. This innovative initiative is part of Ÿnsect's ŸnFABRE project, contributing to the advancement of entomoculture and sustainable solutions in addressing environmental challenges.
In December 2022, The Merck Group, a German-based science and technology company that offers DNA and gene chips, signed a Memorandum of Understanding (MoU) with Synplogen. This partnership aims to advance the development, manufacturing, and testing of viral vector-based gene therapies in Japan. Additionally, Merck will provide practical training for Synplogen's scientists at its M Lab Collaboration Center in Tokyo, facilitating knowledge transfer and technical assistance. Synplogen Co. Ltd. is a Japan-based company specializing in DNA synthesis.
Major companies operating in the DNA and gene chip market are PerkinElmer Inc., Illumina Inc., Thermo Fisher Scientific Inc., Macrogen Inc., Agilent Technologies Inc., Greiner Bio-One International GmbH, CapitalBio Corporation, Microarrays Inc., bioMérieux SA, Applied Microarrays Inc., Biometrix Technology Inc., Oxford Gene Technology IP Limited, Bioneer Corporation, Eurofins MWG Operon LLC, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Bio-Rad Laboratories Inc., BioChain Institute Inc., Cepheid, Eppendorf AG, Fluidigm Corporation, GE Healthcare, Genisphere LLC, Gyros Protein Technologies AB, Hitachi High-Technologies Corporation, LC Sciences.
North America was the largest region in the DNA and gene chip market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna and gene chip market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna and gene chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
A DNA and gene chip is a microchip featuring microscopic DNA probes attached to a solid surface, capable of identifying DNA from test samples and constituting one half of the DNA double helix. When the test sample of DNA carries a mutation, the DNA fails to bind properly to the sequence on the chip. This technology is employed to measure the expression levels of genes or determine whether a person's DNA exhibits mutations, variations in DNA that can lead to diseases.
The main types of DNA and gene chips include oligonucleotide DNA (O-DNA), complementary DNA (C-DNA), and other variations. Oligonucleotide DNA comprises short single- or double-stranded DNA or RNA fragments with three to twenty nucleotides. Products associated with this technology include consumables and instruments, with applications ranging from cancer diagnostics, gene expression, proteomics, genomics, drug discovery, to agrigenomics. End-user industries involved encompass academic and government research institutes, biotechnology and pharmaceutical companies, hospitals and diagnostics centers, among others.
The DNA and gene chips market research report is one of a series of new reports that provides DNA and gene chips market statistics, including DNA and gene chips industry global market size, regional shares, competitors with a DNA and gene chips market share, detailed DNA and gene chips market segments, market trends and opportunities, and any further data you may need to thrive in the DNA and gene chips industry. This DNA and gene chips market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The DNA and gene chip market consists of sales of instrumentation and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The DNA and gene chip market size is expected to see rapid growth in the next few years. It will grow to $15.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in precision medicine, expansion of biomarker discovery, growth of personalized therapeutics, application in cancer research, increasing research funding. Major trends in the forecast period include technological advancements, product innovations, regulatory framework and compliance, focus on rare diseases, continuous reduction in costs.
The DNA and gene chip market is experiencing substantial growth, primarily fueled by the escalating demand for early cancer detection. Cancer, a pervasive health concern, prompts an urgent need for technologies facilitating timely identification. DNA and gene chips play a pivotal role in measuring gene expression, understanding genetic landscapes, and assessing genomic regulatory elements in cancer cells. Notably, the American Cancer Society estimates approximately 1.9 million new cancer cases and 609,360 deaths in the United States for 2022, emphasizing the critical role of DNA and gene chips in advancing early cancer detection.
The growing emphasis on personalized medicine is anticipated to drive the expansion of the DNA and gene chip market in the future. Personalized medicine is an emerging approach in healthcare that utilizes an individual's genetic profile to inform decisions regarding disease prevention, diagnosis, and treatment. DNA and gene chips play a crucial role in personalized medicine by analyzing a person's genetic profile to identify potential disease risks and treatment options. For example, in October 2022, reports from STAT, a US-based health-focused news organization, indicated that there were over 75,000 genetic testing products and 300 personalized medicines available. Consequently, the heightened focus on personalized medicine is fueling the growth of the DNA and gene chip market.
Strategic partnerships and collaborations are emerging as significant trends in the DNA and gene chip market. Many companies in this field are seeking alliances to enhance their positions within the DNA and gene chip market. For example, in June 2022, Avesthagen Limited, an India-based integrated systems biology platform company, established a four-year strategic partnership with Wipro Limited, an India-based information technology firm. This collaboration involves executing the project titled "Cancer Risk Assessed by NGS profiling of circulating free DNA and RNA for lung cancer," which focuses on genomics sequencing services. Additionally, in May 2022, Thermo Fisher Scientific, a US-based supplier of analytical instruments, partnered with the Qatar Genome Program (QGP), part of the Qatar Foundation (QF), to develop a custom Axiom genotyping array for pan-Arab populations using whole genome sequencing data from 19 Arab countries. This array, featuring 800,000 variants, aims to enhance genomic research on conditions such as diabetes, cardiovascular diseases, autism, and cancer. The collaboration supports Qatar's national vision for improved population health and the advancement of precision medicine for Arab individuals globally, facilitated by Thermo Fisher's Axiom microarray technology, which accelerates precision medicine initiatives.
Key players in the DNA and gene chip market are developing innovative genotyping chips, such as the Axiom YNS_Mol1, to advance the food industry and promote insect consumption. The Axiom YNS_Mol1 is a genotyping chip specifically designed for insect breeding, particularly for the Tenebrio Molitor mealworm. For instance, in June 2023, Ÿnsect, a France-based company specializing in insect production, introduced the world's first genotyping chip for insect breeding, the Axiom YNS_Mol1. Developed in collaboration with Thermo Fisher Scientific, this pioneering chip aims to transform insect breeding for sustainable food and pet food production. It analyzes genetic traits to enhance genomic diversity and improve characteristics such as growth, reproduction, and disease resistance in Tenebrio Molitor mealworms. This innovative initiative is part of Ÿnsect's ŸnFABRE project, contributing to the advancement of entomoculture and sustainable solutions in addressing environmental challenges.
In December 2022, The Merck Group, a German-based science and technology company that offers DNA and gene chips, signed a Memorandum of Understanding (MoU) with Synplogen. This partnership aims to advance the development, manufacturing, and testing of viral vector-based gene therapies in Japan. Additionally, Merck will provide practical training for Synplogen's scientists at its M Lab Collaboration Center in Tokyo, facilitating knowledge transfer and technical assistance. Synplogen Co. Ltd. is a Japan-based company specializing in DNA synthesis.
Major companies operating in the DNA and gene chip market are PerkinElmer Inc., Illumina Inc., Thermo Fisher Scientific Inc., Macrogen Inc., Agilent Technologies Inc., Greiner Bio-One International GmbH, CapitalBio Corporation, Microarrays Inc., bioMérieux SA, Applied Microarrays Inc., Biometrix Technology Inc., Oxford Gene Technology IP Limited, Bioneer Corporation, Eurofins MWG Operon LLC, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Bio-Rad Laboratories Inc., BioChain Institute Inc., Cepheid, Eppendorf AG, Fluidigm Corporation, GE Healthcare, Genisphere LLC, Gyros Protein Technologies AB, Hitachi High-Technologies Corporation, LC Sciences.
North America was the largest region in the DNA and gene chip market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna and gene chip market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna and gene chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
A DNA and gene chip is a microchip featuring microscopic DNA probes attached to a solid surface, capable of identifying DNA from test samples and constituting one half of the DNA double helix. When the test sample of DNA carries a mutation, the DNA fails to bind properly to the sequence on the chip. This technology is employed to measure the expression levels of genes or determine whether a person's DNA exhibits mutations, variations in DNA that can lead to diseases.
The main types of DNA and gene chips include oligonucleotide DNA (O-DNA), complementary DNA (C-DNA), and other variations. Oligonucleotide DNA comprises short single- or double-stranded DNA or RNA fragments with three to twenty nucleotides. Products associated with this technology include consumables and instruments, with applications ranging from cancer diagnostics, gene expression, proteomics, genomics, drug discovery, to agrigenomics. End-user industries involved encompass academic and government research institutes, biotechnology and pharmaceutical companies, hospitals and diagnostics centers, among others.
The DNA and gene chips market research report is one of a series of new reports that provides DNA and gene chips market statistics, including DNA and gene chips industry global market size, regional shares, competitors with a DNA and gene chips market share, detailed DNA and gene chips market segments, market trends and opportunities, and any further data you may need to thrive in the DNA and gene chips industry. This DNA and gene chips market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The DNA and gene chip market consists of sales of instrumentation and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. DNA and Gene Chip Market Characteristics3. DNA and Gene Chip Market Trends and Strategies4. DNA and Gene Chip Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global DNA and Gene Chip Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the DNA and Gene Chip Market34. Recent Developments in the DNA and Gene Chip Market
5. Global DNA and Gene Chip Growth Analysis and Strategic Analysis Framework
6. DNA and Gene Chip Market Segmentation
7. DNA and Gene Chip Market Regional and Country Analysis
8. Asia-Pacific DNA and Gene Chip Market
9. China DNA and Gene Chip Market
10. India DNA and Gene Chip Market
11. Japan DNA and Gene Chip Market
12. Australia DNA and Gene Chip Market
13. Indonesia DNA and Gene Chip Market
14. South Korea DNA and Gene Chip Market
15. Western Europe DNA and Gene Chip Market
16. UK DNA and Gene Chip Market
17. Germany DNA and Gene Chip Market
18. France DNA and Gene Chip Market
19. Italy DNA and Gene Chip Market
20. Spain DNA and Gene Chip Market
21. Eastern Europe DNA and Gene Chip Market
22. Russia DNA and Gene Chip Market
23. North America DNA and Gene Chip Market
24. USA DNA and Gene Chip Market
25. Canada DNA and Gene Chip Market
26. South America DNA and Gene Chip Market
27. Brazil DNA and Gene Chip Market
28. Middle East DNA and Gene Chip Market
29. Africa DNA and Gene Chip Market
30. DNA and Gene Chip Market Competitive Landscape and Company Profiles
31. DNA and Gene Chip Market Other Major and Innovative Companies
35. DNA and Gene Chip Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
DNA and Gene Chip Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on dna and gene chip market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dna and gene chip? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dna and gene chip market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Oligonucleotide DNA (o-DNA); Complementary DNA (c-DNA); Other Types2) by Application: Cancer Diagnostics; Gene Expression; Proteomics; Genomics; Drug Discovery; Agrigenomics; Other Applications
3) by End User: Academic and Government Research Institutes; Biotechnology and Pharmaceutical Companies; Hospitals and Diagnostics Centers; Other End Users
Subsegments:
1) by Oligonucleotide DNA (o-DNA): Custom Oligonucleotide Chips; Commercial Oligonucleotide Arrays2) by Complementary DNA (c-DNA): cDNA Microarrays; cDNA Expression Arrays
3) by Other Types: Single-Cell RNA Sequencing Chips; SNP (Single Nucleotide Polymorphism) Chips; Whole Genome Amplification Chips
Key Companies Mentioned: PerkinElmer Inc.; Illumina Inc.; Thermo Fisher Scientific Inc.; Macrogen Inc.; Agilent Technologies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this DNA and Gene Chip market report include:- PerkinElmer Inc.
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Macrogen Inc.
- Agilent Technologies Inc.
- Greiner Bio-One International GmbH
- CapitalBio Corporation
- Microarrays Inc.
- bioMérieux SA
- Applied Microarrays Inc.
- Biometrix Technology Inc.
- Oxford Gene Technology IP Limited
- Bioneer Corporation
- Eurofins MWG Operon LLC
- F. Hoffmann-La Roche Ltd
- QIAGEN N.V.
- Bio-Rad Laboratories Inc.
- BioChain Institute Inc.
- Cepheid
- Eppendorf AG
- Fluidigm Corporation
- GE Healthcare
- Genisphere LLC
- Gyros Protein Technologies AB
- Hitachi High-Technologies Corporation
- LC Sciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 9.27 Billion |
| Forecasted Market Value ( USD | $ 15.35 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
